⌘K

Login Start Free

Home/Filings/4/0001225208-23-002984

4//SEC Filing

Hwang Angela 4

Accession 0001225208-23-002984

CIK 0000078003other

View on SEC.gov Company Profile

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 5:52 PM ET

Size

11.7 KB

Accession

0001225208-23-002984

Insider Transaction Report

Form 4

Period: 2023-02-25

Group President

Transactions

Exercise/Conversion
Common Stock
2023-02-25$22.89/sh+20,273$464,049→ 44,541 total
Tax Payment
Common Stock
2023-02-25$41.75/sh−5,748$239,979→ 38,793 total
Tax Payment
Common Stock
2023-02-25$43.44/sh−9,015$391,612→ 29,778 total
Exercise/Conversion
Stock Appreciation Rights
2023-02-25−20,273→ 0 total
Exercise: $22.89From: 2023-02-25Exp: 2023-02-25→ Common Stock (20,273 underlying)

Holdings

Common Stock
(indirect: By Rule 16b-3 Plan)
28,851
Common Stock
(indirect: By Spouse)
8,532

Footnotes (6)

[F1]The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
[F2]The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
[F3]Price is the closing price of Pfizer common stock on February 24, 2023.
[F4]The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
[F5]Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
[F6]The reporting person disclaims beneficial ownership of the shares held by spouse.

Documents

1 file

4
doc4.xmlPrimary

Issuer

PFIZER INC

CIK 0000078003

Entity typeother

Related Parties

1

filerCIK 0001725474

Filing Metadata

Form type: 4
Filed: Feb 27, 7:00 PM ET
Accepted: Feb 28, 5:52 PM ET
Size: 11.7 KB

View on SEC.gov